Tag Archives: news

Hot Investor Mandate 1: Toronto-Based Single Family Office Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies

3 May

A single family office based in Toronto, Ontario has its main focus on real estate and mining, but is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space. The firm may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 2: Canada-Based VC Partnered with China I-Bank to Invest Up to $10M or More in Life Science Companies in North America

3 May

A venture capital firm based in Canada is making investments out of its first fund which closed at $500M. The fund was jointly established with a leading Chinese investment bank. The firm usually makes initial investments in the range of $5M-$10M with additional capital reserved for follow-on investments, but is capable of making smaller or larger investments. The firm primarily makes straight equity investments, but may consider convertible notes for smaller/earlier rounds. On occasion, public companies may be considered for investment. The firm is open to opportunities globally and will lead rounds as well as co-invest in a syndicate. The firm has no set number of investments it makes per year, but is a relatively nimble firm and able to act quickly when an opportunity presents itself.

The firm’s focus is in health sciences, including therapeutics, devices, diagnostics and health IT. Generally, the firm focuses on assets with clinical data and will invest in up unto Ph. III. The firm will evaluate pre-clinical assets pending there is a strong scientific rationale, and tends to prioritize platform technologies for early-stage assets. As for medical device companies, the firm prefers to see products with clinical data.

The firm prefers to work with experienced management teams, but will consider first time entrepreneurs as well. The firm typically seeks a board seat along with investment and in addition to capital, seeks to add value through developmental, infrastructure and expertise support, as needed, through the firm’s global network. The firm’s approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 3: USA VC Firm Seeks to Invest in All Sectors of Life Sciences, with Focus on Companies Outside of Major Biotech Hubs

3 May

A venture capital firm based in Texas is focused on early and growth-stage biotech and medical device companies. The group is currently raising their second fund and is actively evaluating deals. Initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm looks to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , ,

Hot Investor Mandate 2: Japanese Pharma Launches New Global Initiative to Invest in Early-Stage Companies

26 Apr

A wholly-owned subsidiary of a global pharmaceutical company with headquarters in Japan is focused on developing innovative products in CNS, dermatology, and pain management. In particular, the pharma has established a strong global presence in transdermal patch products, and has several established products on the market.

The pharmaceutical company is seeking novel products for potential in-licensing and partnering opportunities to strengthen their current pipeline. In addition, the company is unveiling a new initiative through which the company will provide investment to early-stage technologies for which the company could help leverage clinical development. The size of investment will largely depend on the company’s stage of development, but the company is open to invest in seed to mid-stage companies. The company is seeking global opportunities.

With the new early-stage investment initiative, the company is interested in investing and partnering beyond the current focus areas: pain, CNS, and dermatology. Because of the company’s deep expertise in transdermal technology, the company can add significant values to companies with NCEs which can be delivered by patches. The company is also interested in reformulation and repositioning opportunities. The company will consider technologies as early as in development/pre-clinical.

The company has no specific management team requirements. The company has a development and regulatory team that can help companies with advancing towards FDA approval as well as Asian market entry, particularly Japan. Because the company has many resources and support to offer to early-stage companies, experienced management team and successful track record would be a plus, but not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 3: Korean Pharmaceutical Company Seeks In-Licensing Opportunities at All Stages, with Strong Interest in NCEs and First-In-Class Drugs

26 Apr

A large pharmaceutical company headquartered in Seoul, South Korea specializes in developing, manufacturing, and supplying pharmaceutical products that contribute to the health and happiness of humankind, including resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and aging. The company’s strengths lie in the development of raw vitamins, probiotics, and antimicrobials, as well as strong market share in clinics and hospitals, and robust experience in marketing, promotion, distribution, and R&D.

The company works with global pharmaceutical companies to manufacture original prescription drugs and utilizes is internal synthesis capacity to manufacture a wide variety of generic prescription drugs. The company is currently expanding into functional health food, medical device, cosmetic, and beverage industries and evolving into a total healthcare company of global proportions. The company is actively seeking early to late-stage drugs globally for in-licensing, co-development, or acquisition.

The company is seeking early to late-stage therapeutic drugs with strong interests in these following indications: oncology, CNS, gastrointestinal (GI), autoimmune, endocrine and metabolic diseases. The company is most interested in NCEs and first/best-in-class MOA.

The company seeks to partner with teams with strong scientific expertise who are working on novel technologies, and is flexible in terms of distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

Hot Investor Mandate 4: Venture Arm of Global Medical Device Company Looking to Invest In or Partner with Early-Stage Companies Developing Platforms for Regenerative Medicine

26 Apr

A venture arm of a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools, is focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient. The firm is focused on early-stage technologies and is flexible in terms of deal structures and partnerships with startup companies, including seed stage equity investments, strategic partnerships, and joint ventures/collaborations. The firm looks to be a dedicated partner working closely with startups to advance technologies and build companies. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s core focus is on tools and bioprocessing platforms for regenerative medicine including, but not limited to, cell and gene therapies. Interests also include therapies that rely on immature or insufficient manufacturing tools and processes. Some examples of the firm’s products include a platelet lysate culture media to expand cell lines, automated fill/finish and thawing devices, a cryogenic vial to protect samples throughout lab processes, a blood filtration system for autologous cell therapy preparation and more.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 1: Subsidiary of Large USA and China-Based Biotech Seeks Investment and In-Licensing Opportunities in Cell & Gene Therapies, Invests Up to $10M

19 Apr

An emerging company with China headquarters is focusing on the development of the best-in-class immunotherapy technology for cancer cure. Teamed up with outstanding immunologists and molecular biologists, the firm has generated a strong pipeline of Chimeric Antigen Receptor (CAR) product candidates to treat a wide variety of liquid and solid tumors. The firm is a subsidiary company of another established public biotech company with offices in USA and China. The firm is actively seeking investment, partnering and licensing opportunities to expand the pipeline of therapeutics and offerings. Typical allocations are $1-10 M.

The firm’s sectors of focus are cell and gene therapies, cell engineering, processing and manufacturing technologies and tools.

The firm may seek a board seat depending upon size of investment. They are open to working with all stages of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →

View Mobile Site